Axerion Therapeutics

About:

Axerion Therapeutics is a biotech company focused on developing innovative therapeutics for neurological diseases and injuries.

Website: http://www.axeriontherapeutics.com

Top Investors: Connecticut Innovations

Description:

Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury. Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.

Total Funding Amount:

$1.15M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New Haven, Connecticut, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)AxerionTherapeutics.com

Founders:

Sylvia McBrinn

Number of Employees:

1-10

Last Funding Date:

2011-10-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai